be tested In the next few days will be another vaccine against the novel Coronavirus in humans. The Paul-Ehrlich-Institute in Langen has allowed the tübingen-based company Curevac to start the clinical trial. The vaccine will be tested in the framework of a so-called Phase 1 study in healthy volunteers.At the end of April already, the Mainz-based company Biontech had received this approval.
Kim-Björn Becker
editor in the policy.
F. A. Z.
The vaccine from Tübingen sollnun in three German test centres in Tübingen, Hannover and Munich, as well as in the Belgian city of Gent will be tested. This must, however, agree with the competent ethics Commission. The vaccine is then administered in three different doses.For each dose of Curevac requires 56 test persons; of them 48 are intended to receive the vaccination, and eight a Placebo. The total of 168 participants must be between 18 and 60 years of age and received two inoculations at intervals of a few days. The aim of the study is to investigate the effectiveness and possible side effects of vaccination. The vaccine had previously been tested in clinical studies in mice.
The application for authorisation of Curevac was approved within nine days by the Paul-Ehrlich-Institute. According to the words of Klaus Cichutek, President of the authority, this was possible because the Institute had operated a “increased staff” and “intensive preliminary talks” with the tübingen-based company announced. “That went well,” said Cichutek on Wednesday. You would suffer due to the increased speed of approval of”no care loss.”
